Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

DOI: 10.1007/s41669-018-0096-x

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text